October 20, 2016 / 11:07 AM / in 10 months

BRIEF-Prometic's PBI-4050 meets primary end point

Oct 20 (Reuters) - Prometic Life Sciences Inc -

* Prometic's PBI-4050 meets primary and secondary end points in metabolic syndrome and type 2 diabetes phase 2 clinical trial

* PBI-4050 has been well tolerated with no serious drug related adverse events

* Clinically and statistically significant reduction of glycated hemoglobin originally observed at 12 weeks is maintained at 24 weeks of treatment

* Placebo-Controlled clinical trial to commence this quarter Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below